Table 4 Budgetary impact results (€, 2010)
From: Budgetary impact analysis of buprenorphine-naloxone combination (Suboxone®) in Spain
Scenario without B/N combination | Scenario with B/N combination | Difference (€) with B/N vs. without B/N | ||
|---|---|---|---|---|
1st year | MAW | 1,724,290 | 2,312,217 | 587,927 |
HTP | 28,428,367 | 28,541,622 | 113,255 | |
LITP | 55,613,472 | 55,735,372 | 121,900 | |
2 nd year | MAW | 1,711,926 | 2,416,973 | 705,047 |
HTP | 22,380,263 | 22,181,969 | -198,294 | |
LITP | 55,763,283 | 55,799,317 | 36,034 | |
3 rd year | MAW | 1,747,500 | 2,642,079 | 894,579 |
HTP | 20,796,602 | 20,476,162 | -320,440 | |
LITP | 56,593,400 | 56,590,723 | -2,677 |